Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Historic Finished Goods for Zevra Therapeutics (ZVRA) over the last 2 years, with Q3 2024 value amounting to $1.1 million.

  • Zevra Therapeutics' Finished Goods changed N/A to $1.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.1 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Zevra Therapeutics reported Finished Goods of $1.1 million as of Q3 2024.
  • In the past 5 years, Zevra Therapeutics' Finished Goods registered a high of $5.1 million during Q1 2024, and its lowest value of $1.1 million during Q3 2024.